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Introduction
Prostate cancer is the most prevalent male cancer in Europe 
and a major cause of cancer- related deaths [1]. Lifestyle 
factors and related intermediate phenotypes have been 
associated with prostate cancer development and progres-
sion in epidemiological studies, including a positive asso-
ciation between circulating cholesterol levels and prostate 
cancer [2–4]. However, conclusions are conflicting and 
it is not clear whether these findings reflect causality or 
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Abstract
Genetic risk scores were used as unconfounded instruments for specific lipid 
traits (Mendelian randomization) to assess whether circulating lipids causally 
influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 
controls from 22 studies within the international PRACTICAL consortium were 
analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previ-
ously reported to be uniquely associated with each of low- density lipoprotein 
(LDL), high- density lipoprotein (HDL), and triglyceride (TG) levels, were first 
validated in an independent dataset, and then entered into logistic regression 
models to estimate the presence (and direction) of any causal effect of each 
lipid trait on prostate cancer risk. There was weak evidence for an association 
between the LDL genetic score and cancer grade: the odds ratio (OR) per 
genetically instrumented standard deviation (SD) in LDL, comparing high- (≥7 
Gleason score) versus low- grade (<7 Gleason score) cancers was 1.50 (95% CI: 
0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly 
associated with stage: the OR for advanced versus localized cancer per unit 
increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The 
rs12916- T variant in 3- hydroxy- 3- methylglutaryl- CoA reductase (HMGCR) was 
inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). 
In conclusion, circulating lipids, instrumented by our genetic risk scores, did 
not appear to alter prostate cancer risk. We found weak evidence that higher 
LDL and TG levels increase aggressive prostate cancer risk, and that a variant 
in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. 
However, inferences are limited by sample size and evidence of pleiotropy.
3© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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are the product of confounding by common causes of 
both cholesterol levels and prostate cancer (e.g., aspects 
of diet), bias, or reverse causality (the cancer causing 
altered cholesterol metabolism) [5]. As serum cholesterol 
levels can be modified by lifestyle changes [6] and statin 
therapy [7], clarifying the causality of this association 
could inform the development of prevention interventions 
for prostate cancer.
Statins lower cholesterol levels by inhibiting HMG- CoA 
reductase, the rate- limiting enzyme in cholesterol synthesis. 
A meta- analysis of 27 observational studies concluded that 
statin therapy reduced prostate cancer by 7% (RR 0.93; 
95% CI: 0.87, 0.99; P = 0.03) [8], but a separate meta- 
analysis of four randomized trials showed minimal evidence 
of any association (RR 1.08; 95% CI: 0.91, 1.30; P = 0.38) 
[9]. Both analyses revealed considerable heterogeneity 
between the included studies (I2 values >70%) and, as 
prostate cancer was assessed as a secondary outcome in 
the trials, misclassification of outcome could have biased 
the results. As yet, evidence regarding statin therapy for 
prostate cancer is controversial [10].
Mendelian randomization uses genetic variants robustly 
associated with traits of interest (in this case, circulating 
low- density lipoprotein [LDL], high- density lipoprotein 
[HDL], and triglyceride [TG] levels) as instrumental vari-
ables to make inferences about whether associations between 
exposures and disease are likely to be causal [11]. The 
principle of Mendelian randomization is that analysis of 
groups defined by common genetic variants is analogous 
to that of an intention- to- treat analysis in a randomized 
controlled trial, based on Mendel’s laws of segregation 
and independent assortment. Using genetic variants as 
“instrumental variables” to proxy modifiable exposures 
should be unconfounded by environmental factors, rep-
resent life- long exposure, and not be subject to reverse 
causality with respect to the phenotype proxied by the 
genotype. A genetic score using several single nucleotide 
polymorphisms (SNPs) in combination can be constructed 
to represent the additive effect of multiple gene variants 
to explain more of the variance in the risk factor of inter-
est, avoiding weak instrument bias, and increasing power 
[12]. Genetic scores using multiple gene variants for lipid 
traits have been used previously to investigate associations 
between blood lipids and vascular disease [13–15]. If the 
instrumental variable assumptions hold, as shown in 
Figure 1, then a test of the association between the instru-
ment and the outcome is a test of the presence of a 
causal effect of the intermediate on the outcome [16].
Here we test for the possible presence of a causal effect 
of lipid fractions (LDL, HDL, TG) on prostate cancer 
using genetic variants for these traits combined in genetic 
risk scores using the principle of Mendelian randomiza-
tion [11]. As far as we know, this study is the first to 
employ Mendelian randomization to investigate the asso-
ciation between circulating lipids and prostate cancer risk.
Methods
Genetic risk scores as instruments for circulating lipid 
fractions were developed using SNPs previously identified 
by genome- wide association studies (GWAS). These scores 
were then applied to 22,249 prostate cancer cases and 
22,133 controls within the international PRACTICAL con-
sortium [17] for whom genetic data were available.
Study populations
PRACTICAL consortium (prostate cancer 
association group to investigate cancer- associated 
alterations in the genome)
We investigated the association between genetic risk scores 
for lipid traits and prostate cancer risk in an individual 
participant meta- analysis of men in 22 studies of the 
international PRACTICAL consortium (Table 1). Fifteen 
of these studies were based in Europe, five in North 
America, and two in Australia. Genotypic information was 
available for 44,382 participants (22,249 prostate cancer 
cases and 22,133 controls). Subjects were predominantly 
of European descent (mean across studies = 99%). All 
studies met the appropriate ethical criteria for each country 
in accordance with the principles embodied in the 
Declaration of Helsinki. Further details are available from 
Figure 1. Mendelian randomization. Using genetic variants as instrumental variables to establish whether an exposure is causally related to cancer. 
An instrumental variable (genetic variation) [Z] acts as a proxy for environmental exposure [X], postulated to influence cancer [Y]. Z is independent of 
measured or unmeasured confounders [U]. Z only influences Y if X →Y is causal.
Genetic risk scores for LDL,  
HDL and TG. Comprised of 
genetic variants [Z]
Circulating LDL, HDL and 
TG [X]
Prostate cancer 
[Y]
Measured and 
Unmeasured 
confounders [U]
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the consortium website (http://www.practical.ccge.medschl.
cam.ac.uk).
Data concerning cancer grade and stage were collected by 
each study. Cancers were categorized as low grade (Gleason 
score ≤6) or high grade (Gleason score ≥7), and localized 
(T1 or T2 on TNM staging, or if not available, “localized” 
on SEER staging) or advanced (T3 or T4 on TNM staging, 
or if not available, “regional” or “distant” on SEER staging). 
Data were not available for grade in two (MEC/UTAH), or 
stage in three (CPCS1/CPCS2/QLD), of the PRACTICAL 
studies, respectively.
GWAS identification of lipid SNPs
SNPs associated with the lipid traits under investigation 
were identified by a review of the current published lit-
erature in which papers concerning lipid SNPs were iden-
tified by entering appropriate search terms into the web 
of science database (“Lipid,” “SNP,” “GWAS”). We selected 
SNPs that were exclusively associated, at genome- wide 
significance, with each lipid trait of interest. The majority 
of SNPs were taken from two landmark lipid GWAS [18, 
19], the latter being the largest genetic association study 
of blood lipid levels to be conducted to date (188,577 
individuals). For completeness, a number of SNPs from 
other publications were also included in the analysis [14, 
20]. The EPIC- Norfolk cohort was used by the referenced 
GWASs to identify SNPs associated with lipid traits; we 
therefore excluded this study from our analysis to reduce 
the chance of under- estimating the causal effect of the 
lipids on prostate cancer.
Genotyping data
PRACTICAL samples were genotyped using an Illumina 
Custom Infinium genotyping array (iCOGS) consisting 
of 211,155 SNPs designed for the Collaborative 
Oncological Gene–Environment Study (COGS) (details 
of which may be found on their website http://www.
cogseu.org). The array was specifically designed for the 
evaluation of genetic variants in breast, ovarian, and 
prostate cancer. As genotypic information was not avail-
able for all SNPs in the genetic risk scores, we also used 
SNPs that had been imputed using IMPUTE2 software 
[21]. As a sensitivity analysis, allele frequencies and ORs 
for prostate cancer outcomes using imputed and geno-
typed data were compared by cross tabulation (Table 
S1). As results were similar, imputed data were used in 
all subsequent analyses. All SNPs with an indication of 
poor imputation quality were removed (r2 hat<0.30), as 
were those with a minor allele frequency of <1%, a call 
rate of <95%, or those that violated the Hardy–Weinberg 
equilibrium (P < 0.05).
Gene variants used to create the genetic risk scores
Genetic risk scores were used as instruments to proxy 
exposure to circulating blood lipids in a Mendelian ran-
domization framework [22]. This analysis assumes that 
the genetic risk scores used in the analysis influence prostate 
cancer risk only via their ability to alter the specific lipid 
trait that they are acting as proxies for (e.g., LDL, Fig. 1). 
If other biochemical processes or traits are associated with 
the genetic risk scores (i.e., horizontal pleiotropy is present, 
where pathways from lipid- associated SNPs to disease are 
involved that are independent of lipids, see Box 1) and 
also directly alter prostate cancer risk, this violates a major 
assumption of Mendelian randomization by introducing 
genetic confounding. Therefore, only SNPs exclusively 
associated at genome- wide significance (P < 5 × 10−8) 
with one lipid trait (either LDL or HDL or TGs, but not 
more than 1) were chosen for each genetic risk scores to 
make them as specific to one trait as possible (as in Holmes 
et al. [15]) (Table S2), minimizing the possibility of pleio-
tropic effects. Of the 118 SNPs identified as associated 
with only one lipid trait, 62 were either genotyped or 
imputed in the PRACTICAL consortium and considered 
eligible for inclusion in the genetic risk scores based on 
current biological knowledge. SNPs selected for the genetic 
risk scores were tested for evidence of linkage disequilib-
rium (LD) using the SNAP pairwise online tool (http://
www.broadinstitute.org/mpg/snap/ldsearchpw.php), an open 
access resource which uses pairwise LD data based on 
phased genotype data from the International HapMap 
project. A threshold r2 value of ≥0.85 was used to indicate 
LD; where SNPs were in LD, the SNP with the largest 
effect on the lipid trait was selected for the genetic risk 
scores. SNP genotypes were coded as 0, 1, or 2 depending 
on exposure to the risk allele. Dosage values (ranging from 
0 to 2) were generated for imputed SNPs. LDL, HDL, 
and TG scores were composed of 11, 36, and 15 SNPs, 
respectively. Genetic risk scores were created by summing 
the number of “risk” alleles that each of the 22,249 pros-
tate cancer cases and 22,133 controls were exposed to, 
such that the greater the number of “risk” alleles a man 
had, the higher the score. “Risk” alleles were those that 
were positively related to serum LDL or TG, or negatively 
related to serum HDL. Published effect sizes (the effect 
Box 1. Pleiotropy
Vertical pleiotropy: A genetic locus is linked to a cascade 
of events. This is not generally a problem for Mendelian 
randomization studies.
Horizontal pleiotropy: A genetic locus is related to mul-
tiple phenotypes. This violates Mendelian randomization 
assumptions.
6 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
C. J. Bull et al.Blood Lipids and Prostate Cancer
of the risk allele on the trait in SD) were applied to each 
SNP and summated to give a “weighted” genetic risk score 
for each trait [23], for each individual man in each study, 
so that when estimating the effect of a unit increase in 
the genetic risk score directly translated to the effect of 
a SD change in the trait upon the outcome.
In a subsidiary analysis we examined the association 
of a SNP in 3- hydroxy- 3- methylglutaryl- CoA reductase 
(HMGCR) (rs12916) in relation to prostate cancer out-
comes. rs12916- T has been used previously to mimic statin 
intervention in order to estimate the causal association 
of statin use with type 2 diabetes and adiposity measures 
[24]. ORs for prostate cancer outcomes were reported 
per rs12916- T allele.
Validation of genetic risk scores and investigation 
of potential pleiotropy in the ALSPAC cohort
The Avon Longitudinal Study of Parents and Children 
(ALSPAC) is a birth cohort established to investigate 
environmental and genetic factors in health and develop-
ment [25]. ALSPAC data were used to validate the genetic 
risk scores as instruments for circulating lipid exposure 
using linear regression. Ten of the 11 SNPs in the LDL 
score could be included in score validation analyses using 
ALSPAC data (due to poor imputation quality in ALSPAC, 
rs1801689 could not be included in the LDL score valida-
tion). Thirty- five of the 36 HDL genetic risk score SNPs 
could be validated in ALSPAC (rs1084651 was poorly 
imputed) and 14 of the 15 TG genetic risk score SNPs 
were available for validation in the ALSPAC cohort 
(rs11649653 was poorly imputed).
Statistical analysis
The genetic risk scores were entered into logistic regres-
sion models to estimate the effect per genetically 
instrumented SD increase in the lipid trait on prostate 
cancer outcomes.
Outcomes investigated were: all prostate cancer (case 
vs. control status), grade (high [≥7] versus low [≤6] Gleason 
score), and stage (advanced versus localized TNM or SEER 
staging). We conducted the analyses within each of the 
individual studies that make up the PRACTICAL 
 consortium and then combined the results into a sum-
mary odds ratio (OR) for each outcome per unit increase 
in the genetic risk scores by fixed effect meta- analysis 
using the “metan” command in Stata v.13 [26]. To test 
that the instruments (genetic risk scores) were not associ-
ated with confounders, we investigated whether each genetic 
risk score was associated with available covariables that 
could be potential confounding factors (age, diagnostic 
prostate specific antigen (PSA) levels, and family history 
of prostate cancer). To account for potential confounding 
by population stratification, we adjusted for the top eight 
principle components (variables concerning the popula-
tion’s genetic architecture). All analyses were performed 
in Stata v.13 (Stata Corp LP, 2013, College Station, TX).
Results
The genetic risk scores were validated in ALSPAC par-
ticipants at the age of 7 years (Table 2). The genetic risk 
score for LDL explained 0.3% of the variability in circu-
lating LDL and not only was most strongly associated 
with LDL (linear regression coefficient; 0.56 mmol/L LDL; 
F stat: 14.11; P = 2 × 10−4), but was also weakly associ-
ated with HDL (linear regression coefficient; 0.19 mmol/L 
HDL; F stat: 5.32; P = 0.02). The HDL genetic risk score 
was the strongest instrument, explaining 0.9% of variability 
in circulating HDL and was associated exclusively with 
HDL (linear regression coefficient; −0.25 mmol/L HDL; 
F stat: 37.60; P = 9.5 × 10−10). The TG genetic risk score 
was most strongly associated with TG and explained 0.2% 
Table 2. Weighted genetic risk score validation in ALSPAC (N = 4081).
Genetic risk score
Change in trait levels  
(mmol/L) per unit score1 95% CI P value r2 (%) F
LDL (10 SNPs)
LDL 0.56 0.27, 0.86 2 × 10−4 0.34 14.11
HDL 0.19 0.03, 0.35 0.021 0.13 5.32
lnTG −0.18 −0.41, 0.06 0.141 0.05 2.17
HDL (35 SNPs)
HDL −0.25 −0.32, −0.17 9.50 × 10−10 0.91 37.60
LDL −0.12 −0.25, 0.04 0.16 0.05 1.97
lnTG 0.05 −0.06, 0.17 0.36 0.02 0.36
TG (14 SNPs)
lnTG 0.35 0.13, 0.57 0.002 0.24 9.76
LDL 0.12 −0.16, 0.39 0.40 0.02 0.70
HDL −0.19 −0.34, −0.04 0.01 0.15 6.28
1TG levels have been natural log transformed.
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of the variability in circulating TG (linear regression coef-
ficient; 0.35 mmol/L lnTG; F stat: 9.76; P = 2 × 10−3); 
however, it was also associated with HDL (0.15% variability 
explained, linear regression coefficient; −0.19 mmol/L HDL; 
F stat: 6.28; P = 0.01). Associations of the genetic risk 
scores with each lipid trait remained unaltered following 
stratification of participants by sex (data available on 
request).
Individual data from 22,249 case and 22,133 control 
men in 22 PRACTICAL studies were included in our 
analysis (Table 1). The percentage of high- grade cancers 
reported varied between studies (27.9–84.2%), as did the 
proportion of advanced stage cancers (3.5–46.7%). There 
was little evidence to support an association between 
genetic risk scores and PSA at recruitment. Family history 
of prostate cancer was weakly, and imprecisely, associated 
with the LDL (OR: 0.50, 95% CI: 0.21, 1.19; P = 0.12) 
and HDL (OR: 1.62, 95% CI: 1.02, 2.58; P = 0.04) genetic 
risk scores. Four of the top eight principal components 
were associated with at least one of the genetic risk scores. 
Age at interview was not associated with the genetic risk 
scores, with the exception of the TG score (linear regres-
sion coefficient: −2.76, 95% CI: −5.52, −0.0003; P = 0.05) 
(Table 3).
The pooled ORs for overall prostate cancer risk by 
lipid trait, estimated in instrumental variable analysis using 
the genetic risk score, were 1.24 (95% CI: 0.90, 1.69; 
P = 0.18; I2 = 4.4%), 0.99 (95% CI: 0.84, 1.17; P = 0.90; 
I2 = 0%), and 1.09 (95% CI: 0.80, 1.50; P = 0.57; 
I2 = 14.4%) per genetically instrumented SD increase in 
LDL, HDL, and TG, respectively (Fig. 2).
The ORs for prostate cancer outcomes stratified by 
grade and stage are summarized in Table 4. There was 
weak evidence to suggest an effect for a genetically instru-
mented SD increase in LDL between high- versus low- 
grade cancer cases (OR: 1.50; 95% CI: 0.92, 2.46; P = 0.11). 
There was little evidence to suggest an association between 
the HDL and TG genetic risk scores and prostate cancer 
grade: When high- and low- grade cancers were compared, 
a genetically instrumented SD decrease in HDL gave an 
OR of 1.03 (95% CI: 0.79, 1.34; P = 0.82), and a geneti-
cally instrumented SD increase in TG gave an OR of 
0.93 (95% CI: 0.57, 1.52; P = 0.77). For cancer stage, a 
genetically instrumented SD increase in LDL gave an OR 
for advanced versus localized cancers of 0.91 (95% CI: 
0.51, 1.64; P = 0.77). A genetically instrumented SD 
decrease in HDL gave an OR for advanced versus local-
ized cancers of 1.02 (95% CI: 0.74, 1.39; P = 0.92). The 
OR for advanced versus localized prostate cancer per SD 
genetically instrumented increase in TG was 1.68 (95% 
CI: 0.95, 3.00; P = 0.08).
EPIC- Norfolk was excluded from the analysis, as the 
cohort was included in the referenced GWAS discovery 
panels. As a sensitivity analysis, we included EPIC- Norfolk 
in the meta- analysis. The results for EPIC- Norfolk were 
in agreement with the combined estimates for the odds 
of prostate cancer by the genetic risk scores (Fig. S1). As 
some associations were present between the genetic risk 
scores and family history or age at diagnosis (Table 3), 
we performed a sensitivity analysis adjusting for these 
variables. The results were unaltered following adjustment 
for age with the TG score and for family history with 
the LDL and HDL scores (data available on request).
The rs12916- T variant in HMGCR was weakly associ-
ated with a decreased risk of prostate cancer overall (OR: 
0.97; 95% CI: 0.94, 1.00; P = 0.03; I2 = 0%) (Fig. 3). 
Table 3. Association genetic risk scores with potential confounding variables in 22,133 PRACTICAL control men.
Variable n LDL HDL TG
Change in variable per unit increase genetic risk score1 (95% CI), P value
 Principle component 1 22,133 −0.20 (−0.45, 0.04), 0.10 −0.08 (−0.29, 0.14), 0.47 −0.17 (−0.51, 0.16), 0.30
 Principle component 2 22,133 0.80 (0.43, 1.17), 2 × 10−4 −0.06 (−0.19, 0.07), 0.35 0.70 (0.24, 1.15), 4 × 10−3
 Principle component 3 22,133 −0.54 (−0.81, −0.27), 4 × 10−4 0.01 (−0.10, 0.12), 0.82 −0.36 (−0.60, −0.13), 4 × 10−3
 Principle component 4 22,133 0.28 (−0.19, 0.74), 0.23 0.06 (−0.15, 0.28), 0.54 −0.49 (−0.82, −0.16), 0.01
 Principle component 5 22,133 0.35 (−0.18, 0.87), 0.18 −0.10 (−0.29, 0.09), 0.29 0.21 (−0.20, 0.63), 0.30
 Principle component 6 22,133 −0.56 (−1.00, −0.15), 0.01 0.11 (−0.06, 0.28), 0.19 0.19 (−0.19, 0.57), 0.32
 Principle component 7 22,133 −0.08 (−0.39, 0.23), 0.61 0.23 (−0.06, 0.53), 0.11 0.03 (−0.39, 0.44), 0.90
 Principle component 8 22,133 0.28 (−0.19, 0.75), 0.22 0.03 (−0.18, 0.25), 0.75 0.09 (−0.23, 0.41), 0.58
 PSA (ng/mL) 5012 −0.08 (−1.79, 1.63), 0.86 −0.16 (−0.56, 0.23), 0.22 0.17 (−0.42, 0.76), 0.35
 Age (years) 18,962 −0.68 (−3.80, 2.43), 0.65 −0.33 (−2.24, 1.58), 0.73 −2.76 (−5.52. −0.0003), 0.05
OR family history per unit increase in genetic risk score (95% CI), P value
 Family history2 10,955 0.50 (0.21, 1.19), 0.12 1.62 (1.02, 2.58), 0.04 0.60 (0.25, 1.42), 0.24
Studies with more than 20% missing data were excluded from each analysis. Linear regression models take clustering by substudy into account.
LDL, low- density lipoprotein; HDL, high- density lipoprotein; TG, triglyceride; OR, odds ratio.
1Higher LDL/TG scores reflect increasing circulating LDL/TG, higher HDL scores reflect lower circulating HDL.
2Family history of prostate cancer (in father or brother): compares Yes versus No (logistic regression).
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There was little evidence of an association with prostate 
cancer stage (OR, advanced vs. localized: 0.97; 95% CI: 
0.92, 1.02; P = 0.26) or grade (OR, high vs. low: 1.03; 
95% CI: 0.98, 1.07; P = 0.21) (Table 5).
Discussion
We did not find evidence to suggest an association between 
circulating LDL, HDL, or TG (proxied by genetic risk 
scores) and overall prostate cancer. Although power to 
investigate advanced/high- grade cancer is limited (as evi-
denced by wide confidence intervals), our results may 
indicate a potential role for LDL and TG in prostate 
cancer progression. These findings are clinically important, 
as they highlight a distinction between indolent disease 
and more aggressive cancers. Variation in HMGCR has 
been exploited previously to demonstrate the implications 
of statin treatment on type 2 diabetes and bodyweight 
[24]. Our results from an analysis using a variant in 
HMGCR (rs12916- T) to proxy statin intervention suggest 
that statins may hold potential in prostate cancer preven-
tion, but our inference is tentative and requires further 
investigation in larger sample sizes. Associations observed 
between the LDL and HDL genetic risk scores and family 
history findings may be an artifact of multiple testing. 
However, these findings warrant further investigation with 
larger numbers to increase the precision of the point 
estimates.
Meta- analyses of observational studies and randomized 
controlled trials present heterogeneous findings for asso-
ciations of cholesterol with prostate cancer, making it 
difficult to conclude whether cholesterol plays a role in 
prostate cancer. The most recent and comprehensive assess-
ment of observational data did not show any association 
between HDL and LDL and prostate cancer, but could 
not draw definitive conclusions on high- grade prostate 
cancer due to limited data [5]. Our Mendelian randomi-
zation approach has several advantages over conventional 
observational epidemiology: it eliminates the problem of 
reverse causality, as prostate cancer status cannot alter 
Table 4. Case- only analysis: weighted genetic risk scores and prostate cancer stage and grade (PRACTICAL consortium).
Outcome
Localized/low  
grade (n)
Advanced/high  
grade (n) OR1 95% CI P value
LDL score
Advanced versus localized 13,707 4301 0.91 0.51, 1.64 0.77
High grade versus low grade 9237 8515 1.50 0.92, 2.46 0.11
HDL score
Advanced versus localized 13,707 4301 1.02 0.74, 1.39 0.92
High grade versus low grade 9237 8515 1.03 0.79, 1.34 0.82
TG score
Advanced versus localized 13,707 4301 1.68 0.95, 3.00 0.08
High grade versus low grade 9237 8515 0.93 0.57, 1.52 0.77
Advanced (T3 to T4 or SEER staging regional or distant), localized (T1 to T2 or SEER staging localized), high grade (Gleason ≥7), low grade (Gleason ≤6).
LDL, low- density lipoprotein; HDL, high- density lipoprotein; TG, triglyceride; OR, odds ratio.
1Per unit increase in genetic risk score (SD trait), adjusted for top eight principal components (higher LDL/TG scores reflect increasing circulating LDL/
TG, higher HDL scores reflect lower circulating HDL).
Figure 2. Meta-analysis OR prostate cancer per unit increase in genetic risk scores (SD trait). (A) Low-density lipoprotein (LDL): OR 1.24 
(95% CI: 0.90, 1.69), P = 0.18. (B) High-density lipoprotein (HDL): OR 0.99 (95% CI: 0.84, 1.17), P = 0.90. (C) Triglyceride (TG): 1.09 (95% CI: 
0.80, 1.50), P = 0.57. Cases: 22,249; controls: 22,133. Adjusted for top eight principle components.
A B C
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one’s germline genetic makeup; genetic risk scores rep-
resent an individual’s exposure to lipid traits over their 
lifetime, reducing biological and technical sources of meas-
urement error that arise from one- off blood sampling at 
one point in a person’s life; and confounding by behavioral, 
lifestyle, and other related intermediate traits should be 
minimized as individuals are effectively randomly allocated 
to a low or high level of exposure based on their geno-
type, randomly generated at conception (Mendel’s second 
law of independent assortment) [27]. However, Mendelian 
randomization is susceptible to genetic confounding if 
the SNPs used as instruments for the trait of interest 
have effects on other phenotypes besides the specific lipid 
of interest, and it is these other phenotypes which lead 
to prostate cancer (horizontal pleiotropy) [16]. There is 
also potential for confounding due to population strati-
fication; however, as we have adjusted for principle 
components in our regression models, this should be 
minimized. We cannot be sure that the LDL score is 
exclusively associated with LDL as validation of the score 
in ALSPAC revealed possible pleiotropy with circulating 
HDL. However, the HDL score which is strongly associ-
ated with HDL, and not LDL or TG in ALSPAC, was 
not associated with prostate cancer; therefore, the weak 
association noted between the LDL score and high- grade 
prostate cancer is likely an LDL, not an HDL effect. As 
F statistics for the genetic risk scores relate to ALSPAC 
and not PRACTICAL (the dataset for the outcome), con-
ventional thresholds, such as F > 10 are not relevant for 
this study. The dataset for the outcome is far larger than 
the dataset in which we tested the genetic risk score–trait 
association; therefore, it may be that the genetic risk scores 
are in fact stronger instruments for circulating lipid traits 
in PRACTICAL than we estimated.
Figure 3. Cases versus controls. Meta- analysis OR prostate cancer per rs12916- T allele. OR 0.97 (95% CI: 0.94, 1.00), P = 0.03. Cases: 22,733; 
controls: 23,050. Adjusted for top eight principle components.
Table 5. Stratified analysis by cancer stage and grade. OR per rs12916- T allele. Adjusted for top eight principle components.
Outcome
Localized/low  
grade (n)
Advanced/high  
grade (n) OR 95% CI P value
rs12916- T allele
Advanced versus localized 13,707 4301 0.97 0.92, 1.02 0.26
High grade versus low grade 10,038 8543 1.03 0.98, 1.07 0.21
Advanced (T3 to T4 or SEER staging regional or distant), localized (T1 to T2 or SEER staging localized), high grade (Gleason ≥7), low grade (Gleason ≤6).
OR, odds ratio.
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A recent meta- analysis of 14 prospective studies reported 
that blood LDL and HDL were not associated with either 
overall prostate cancer or high- grade cancers; however, 
subgroup analysis was only performed on a limited number 
of studies and it is likely that the study was underpowered 
to detect any effect of these traits on cancers stratified 
by stage and grade [5]. Our findings suggestive of a pos-
sible role for LDL in high- grade prostate cancer and for 
TG in advanced stage prostate cancer are supported by 
Andreassen et al., who found evidence of an association 
between these traits and prostate cancer with the use of 
an alternative genetic epidemiologic method [28]; however, 
this analysis was also conducted with data obtained from 
the PRACTICAL consortium. Using conjunction false 
discovery rate analysis, they were able to combine sum-
mary statistics from GWAS for the identification of genetic 
overlap between the two phenotypes (blood lipids and 
prostate cancer). Similarly, they found no pleiotropic 
enrichment for HDL in prostate cancer.
A meta- analysis of 27 observational studies reported a 
7% relative reduction in total prostate cancer risk with 
statin therapy [8]. Our results for the rs12916- T SNP 
and prostate cancer outcomes support similar conclusions; 
however, it is possible that the observed effects are via 
the increase in type 2 diabetes phenotypes associated with 
this allele [24], as an inverse association between type 2 
diabetes and prostate cancer has been reported [29].
Cholesterol is thought to have multiple procancer effects 
at the cellular level: it is involved in cellular proliferation, 
inflammation, membrane organization, and steroidogen-
esis. Our findings are supported by preclinical work show-
ing increasing concentrations of LDL support the 
proliferation of prostate cancer cell lines, but not normal 
epithelial cells, suggesting cholesterol metabolism is repro-
grammed in prostate cancer [30]. Furthermore, as signal 
transduction proteins are located in cholesterol- rich mem-
branes, it makes sense that oncogenic signaling might be 
regulated in a cholesterol- sensitive manner [31]. As statins 
are largely retained in liver, any effects on prostate cancer 
are not likely directly on the tissue, but via their ability 
to reduce circulating cholesterol [32]. Statins have also 
been associated with similar cancer phenotypes in cellular 
and animal models, indicating that the effects of statins 
observed in populations are likely due to on- target effects 
of statins (i.e., their ability to reduce circulating cholesterol 
via HMG- CoA reductase inhibition) rather than off- target 
effects, although these have been reported [33–35]. Further 
research on this subject is needed, as previous work has 
found that statins differentially affect prostate cancer 
depending on their subtype [36] and the cancer phenotype 
[32].
A large number of genes robustly associated with serum 
lipids were used in the generation of genetic risk scores 
and their association (at genome- wide significance level) 
with just one of the lipid traits may mitigate against results 
being due to pleiotropy with other lipids. However, key 
SNPs likely regulate multiple traits, so would therefore 
have been excluded from our analysis. This highlights a 
complication in investigating complex traits and the bio-
logical complexity of homeostatic mechanisms: it is hard 
to encompass the variability in a given lipid trait while 
keeping the genetic risk score specific; this is likely reflected 
by the magnitude of the r2 statistics in our score valida-
tion (Table 1). We would have liked to adjust for statin 
use in our analyses; however data were not available. By 
including patients who are taking statins in our analysis 
we may have reduced the true effects of the genetic risk 
scores on prostate cancer outcomes.
We conclude that this study presents tentative evidence 
of a potential role for LDL and TG levels in prostate 
cancer etiology, but not for HDL. These inferences assume 
Mendelian randomization assumptions (such as absence 
of pleiotropy) hold. Future work will involve developing 
stronger and more specific instruments for circulating lipid 
traits, and making use of new instrumental variable meth-
ods, such as Egger regression which controls for pleiotropy 
[37]. If confirmed, these findings are potentially of trans-
lational importance as they indicate that lowering LDL 
cholesterol may be beneficial in reducing risk of high- grade 
prostate cancer.
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